SUVN-D4010

A US-IND approved drug candidate is undergoing phase 1 studies in USA. SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s and Schizophrenia. 5-HT4 receptor offers a novel and unique opportunity to develop compounds for the treatment of AD which combines the symptomatic relief (pro-cognitive) and disease modification.